Evotec SE and its new partner Resolute Therapeutics, a specialist in antimicrobial resistance (AMR), have received a US$8.4m funding from CARB-X for co-development of a first-in-class antibiotic.
COVID-19 has put life science research companies into the limelight. An Interview with Raimund Gabriel, founder and managing director MC Services AG, on the role of corporate communications in the corona crisis.
An ongoing crisis and evolving new working habits of industry executives call for an entirely new and up-to-date partnering format. Workarounds such as moving a partnering events scheduled one-on-one meetings online is neither imaginative nor does it meet the requirements of flexibility and effectiveness. The format presented here sounds the bell for a new era of pharma partnering.
BioNTech SE and its partner Fosun Pharma Co. Ltd have selected another COVID-19 vaccine candidate for Phase I testing in China than tested in global Phase III trials.
Evotec SE has secured a strategic partnership with Secarna Pharmaceuticals GmbH to co-develop a LNA drug pipeline.
Rapid tests have received a lot of attention during the Coronavirus pandemic, but as the number of tests available has increased, so has the confusion around the different types and what they can deliver. What if there were laboratory quality tests that could produce a result in just a few minutes?
The European Commission has reserved 300 million doses from Sanofi SA/GSK plcs adjuvanted recombinant COVID-19 vaccine.
Viral pandemics are not a once-in-a-lifetime event but a constant threat looming over our heads. While the fight against SARS-CoV-2 is currently a top priority, we should not lose sight of what might come next. Broad-spectrum antiviral drugs like Atrivas ATR-002, currently in Phase II clinical development for treating COVID-19, could be an effective measure in the fight against the current pandemic and future viral outbreaks.
Roche has reported the failure of its IL-6R antagonist tocilizumab in patients with COVID-19 putting the efficacy of IL-6 inhibition at question.
Italian start-up Enthera Pharmaceuticals has raised €28m to advance restorative therapy for type 1 diabetes and inflammatory bowel disease.